Introduction
Circulating endothelial progenitor cells (EPCs) are mobilized endogenously in response to tissue ischaemia and thereby augment neovascularization of ischaemic tissues. 1, 2 In patients with acute myocardial infarction (AMI), EPCs, usually defined as CD34 þ progenitor cells, are increased in peripheral blood and are rapidly recruited to myocardium mediating a protective effect of ischaemic preconditioning. 3 -5 Myocardial regeneration via stem-cell mobilization at the time of myocardial infarction is known to occur, although the mechanisms for stem-cell mobilization and subsequent domiciliation to infarcted tissue are poorly understood. Stromal-cell-derived factor-1 (SDF-1, also known as CXCL12) is a powerful chemoattractant for stem and progenitor cells and is essential for both homing (migration, retention, and development) and trafficking (mobilization) of CD34 þ progenitor cells to bone marrow or peripheral blood, respectively. 6 -10 Human CD34 þ stem-cell transendothelial migration, engraftment, and repopulation of murine bone marrow 11, 12 and ischaemia-induced recruitment and differentiation to EPCs 13 -15 are found to be regulated by the chemokine SDF-1 binding to its receptor CXC chemokine receptor 4 (CXCR4), as thoroughly described in different in vitro and in vivo models. Overexpression of CXCR4 on human CD34 þ progenitors increases their proliferation, migration, and bone marrow repopulation. 16 Locally injected SDF-1 into ischaemic hindlimb muscle of immuno-deficient mice combined with human EPC transplantation results in an augmentation of EPC-induced vasculogenesis. This contribution to ischaemic neovascularization in vivo was mediated by increasing EPC recruitment into the ischaemic tissues. 7 The SDF-1/CXCR4 axis seems particularly important in stem/muscle progenitor cell homing, chemotaxis, engraftment, and retention in ischaemic myocardium in vivo. SDF-1 is sufficient to induce therapeutic stem cells homing to injured myocardium and suggests a strategy for directed stem-cell engraftment into injured tissues. 17 SDF-1/CXCR4 interactions play a crucial role in the recruitment of bone-marrow-derived cells to the heart after MI and can further increase homing in the presence, but not in the absence of injury in vivo. 18 Overexpression of SDF-1 enhances endothelium-supported transmigration, maintenance, and proliferation of haematopoietic progenitor cells. 19 Furthermore, hypoxia-inducible factor-1 (HIF-1)-induced SDF-1 expression increases the adhesion, migration, and homing of circulating CXCR4 þ progenitor cells to ischaemic tissue. 20 Blockade of SDF-1 in ischaemic tissue or inhibition of CXCR4 on circulating cells prevents progenitor cell recruitment to sites of injury, indicating that the recruitment of CXCR4 þ progenitor cells to regenerating tissues is mediated by hypoxic gradients via HIF-1-induced expression of SDF-1. 20 However, the origin, regulation, and the impact of SDF-1 in circumstances where tissue regeneration is needed are incompletely understood. Nevertheless, the pathophysiological role of SDF-1 in myocardial ischaemia has been mainly studied in animal models. These results cannot be uncritically transferred into human situation. Therefore, clinical studies are needed to elucidate the role of SDF-1 in humans. Platelets are the first circulating blood cells that interact with the injured vessel wall playing a role not only in atherogenesis, but also in vascular and tissue regeneration. 21, 22 Recently, we reported that platelets recruit bone-marrow-derived progenitor cells to arterial thrombi in vivo involving platelet P-selectin and GPIIb/IIIa integrin and that activated platelets secrete SDF-1 supporting the migration of murine embryonic EPCs and the accumulation of bone-marrow-derived progenitor cells into the platelet-rich thrombus in vivo. 14, 23 Moreover, haematopoietic cytokines, through graded deployment of SDF-1 from platelets, support mobilization and recruitment of CXCR4 þ vascular endothelial growth factor receptor-1 (VEGFR1)-positive haemangiocytes in mice. 24 Furthermore, we recently showed that platelet-derived SDF-1 regulates vascular injury-dependent adhesion and promotes differentiation of human CD34 þ cells to an endothelial phenotype. 15 However, no study has addressed the role of plateletbound SDF-1 in humans, specifically in patients with myocardial ischaemia or infarction.
The aim this study was to evaluate the platelet-bound SDF-1 expression and its correlation with platelet activation, plasma levels of SDF-1, and number of CD34 þ progenitor cells in patients with coronary artery disease and/or reduced left ventricular (LV) function.
Subjects and methods

Patients
Nine hundred and forty-three patients were initially assessed for inclusion into the study. Thirty-nine patients refused to give their consent and therefore were not included in our analysis. A total of 904 consecutive patients were recruited in a pre-planned time period. Four hundred and eighty-six patients with suspected or known coronary artery disease with typical symptoms for stable angina pectoris (SAP) were referred to our hospital for coronary angiography according to the ACC/AHA guidelines for coronary angiography. 25 Patients with SAP had either typical angina on exertion and/or a pathological exercise test and were negative for markers of myocardial ischaemia (troponin, creatinine kinase). Four hundred and eighteen patients presented in our emergency room with an acute coronary syndrome (ACS), as previously defined, 26, 27 were immediately proceeded to percutaneous coronary intervention (PCI). In the means of a subgroup analysis, patients with an ACS were further classified as patients with a non-ST-segment elevation myocardial infarction (NSTEMI), a ST-segment myocardial infarction (STEMI), or an unstable angina with co-existence of positive troponin (Tn þ ACS). Coronary interventions were performed within 6 h after admission to the hospital in patients with ACS. Patients with SAP were investigated on schedule. In a subgroup of 101 consecutive patients, we determined the expression of platelet-bound SDF-1 in relation to the time. The study was approved by the institutional ethical committee and all subjects gave their written informed consent.
Sample collection
Arterial blood was drawn from the sheath that was introduced into the femoral artery at the beginning of coronary intervention and after administration of 2500 U of unfractionated heparin. Arterial blood was filled into 5 mL vials containing citrate phosphate dextrose adenine (CPDA) and analysed by flow cytometry according to standard methods. 28 Cardiac markers were determined at time of hospital admission and 4-6 and 12-24 h after cardiac catheterization. In the subgroup of 101 consecutive patients, we determined the expression of platelet-bound SDF-1 in relation to the time and therefore blood probes were collected every day after the coronary intervention till the fourth day.
Left ventricular function determination
Left ventricular function was determined by standard LV angiography (single-panel method) for evaluation of ejection fraction (EF). Based on a previous study describing the association of LVEF with mortality in stable outpatients with heart failure, 29 we analysed the association between LVEF as a continuous variable with platelet-bound SDF-1.
Whole blood flow cytometry
Platelets obtained from 904 consecutive patients were studied for surface expression of SDF-1, platelet collagen receptor GPVI (4C9), and GPIb (CD42b) by flow cytometric analysis as previously described. 30 Surface expression of P-selectin (CD62P) and acti- , and activated form of GPIIb/IIIa (PAC-1, Becton Dickinson, USA; clone SP-2) with a twocolour flow cytometry in patients' whole blood as previously described. The anti-GPVI mAb 4C9 was generated and characterized as previously described. 31, 32 In brief, 10 ml of CPDA-blood was resuspended 50:1 with phosphate-buffered saline (PBS; Invitrogen Corporation, Paisley, Scotland, UK) and was incubated for 30 min with the relevant conjugated antibodies in the dark at room temperature. After staining, the cells were fixed with 0.5% paraformaldehyde and stored at 48C until fluorescence-activated cell sorting (FACS) was performed with a FACS-Calibur Flow Cytometer (Becton-Dickinson, Heidelberg, Germany). CD42b-PE served as a control antibody to identify the platelet population in the whole blood. Specific monoclonal antibody binding was expressed as mean fluorescence intensity (MFI) and was used as a quantitative measurement of platelet proteins' surface expression.
Enzyme-linked immunosorbent assay
Plasma levels of SDF-1 were determined in a subgroup of 566 consecutive patients with symptomatic coronary artery disease on time of platelet determination using a commercially available enzyme-linked immunosorbent assay kit according to the manufacturer's guidelines (R&D Systems, Minneapolis, MN, USA). Ethylenediamine tetraacetic acid plasma probes were centrifuged for 15 min at 10 000 g within 30 min of collection. Probes were aliquotted and stored at 2208C before analysis. The lower detection limit of this assay is 18 pg/mL. The mean centred coefficient of variation for soluble SDF-1 was 3.2%, thus allowing a relatively good reproducibility of our measurements. 
Peripheral blood mononuclear cell isolation and flow cytometry
Arterial blood was drawn from the femoral artery before cardiac catheterization and buffered with 20 mL of sodium citrate. Mononuclear cells were isolated using a Ficoll density gradient (Biocoll, Biochrom, Berlin, Germany) according to standard protocols, as previously described. 33 For FACS analysis, mononuclear cells were resuspended in 100 mL of PBS. Immunofluorescence cell staining was performed in duplicate with the use of the fluorescent conjugated antibody CD34-FITC (10 mL; Becton Dickinson, San Jose, USA; clone 8G12). IgG1 -FITC antibody (BD Biosciences Pharmingen, USA; clone MOPC-21) served as a negative isotype control. Cell fluorescence was measured immediately after staining, and data were analysed with the use of CellQuest software (FACSCalibur, Becton Dickinson, Heidelberg, Germany). Units of all measured components are absolute cell counts obtained after the measurement of 250 000 events in the lymphocyte gate.
Data presentation and statistical analysis
Data are presented as mean+standard deviation (SD 
Results
Platelet-surface expression of stromal-cell-derived factor-1 is increased in acute coronary syndrome
We first analysed the surface expression of SDF-1 in a consecutive cohort of 904 patients with symptomatic coronary artery disease including ACS (n ¼ 418) and stable coronary artery disease (SAP; Patients with stable angina pectoris or acute coronary syndrome were followed-up for up to 1 or 4 days, respectively, in order to examine the expression of platelet stromal-cell-derived factor-1 in relation to time. *P 0.05 when compared with respective stable angina pectoris. # P 0.05 when compared days 2 -4 with day 1.
Platelet-bound SDF-1 in ACS n ¼ 486). In all patients, the diagnosis was verified and the severity of the disease was assessed by coronary angiography. The demographic details are given in Table 1 . We found that platelet SDF-1 surface expression was significantly enhanced in ACS compared with SAP (ACS (MFI+SD): 18.45 + 12.85; SAP: 13.48 + 5.27; P , 0.001; Figure 1A and B). Patients with ACS were further subdivided into patients with STEMI, NSTEMI, or troponin I-positive ACS (Tn þ ACS). We did not observe any statistical significant difference between these subgroups. However, each of these subgroups showed a significant increase in platelet SDF-1 expression levels when compared with patients with SAP ( Figure 1C) . SDF-1 expression neither correlated nor was influenced, respectively, by cardiovascular risk factors (arterial hypertension, hyperlipidaemia, diabetes mellitus, family history of coronary artery disease, and smoking), the extent of the disease (1/2/3-vessel disease), initial creatinine kinase, troponin, gender, or the received baseline medications ( Table 2) . C-reactive protein (CRP) slightly, but significantly, influences the levels of SDF-1 (point estimate equal to 0.52). On the other hand, no significant correlation was observed between platelet-bound SDF-1 and CRP (data not shown).
In order to determine the expression of SDF-1 over the time, 101 consecutive patients with SAP (n ¼ 73) or ACS (n ¼ 28) were followed-up for 24 h. The patients with ACS were further followed-up for up to 4 days measuring their SDF-1 expression every 24 h. We found that platelet-surface expression of SDF-1 remained significantly increased for 24 h in patients with ACS being followed by a significant decrease in the following days after the acute event ( Figure 1D ).
Stromal-cell-derived factor-1 is increased in patients with reduced left ventricular function
Enhanced platelet-bound SDF-1 expression was found in patients with reduced left ventricular ejection fraction (LVEF ,55%; n ¼ 434) in comparison to patients with normal LVEF (.55%; n ¼ 470; P ¼ 0.005; Figure 2A ). In patients with SAP, platelet-bound SDF-1 expression was increased in patients with reduced LVEF (n ¼ 209) when compared with patients with normal LVEF (n ¼ 277; MFI+SD: normal vs. reduced LVEF: 13.35 + 7.08 vs. 15.03 + 8.59; P ¼ 0.019; Figure 2B ). In a similar manner, in patients with ACS, platelet-bound SDF-1 expression was increased in patients with reduced LVEF (n ¼ 225) when compared with patients with normal LVEF (n ¼ 193; MFI+SD: normal vs. reduced LVEF: 15.88 + 10.47 vs. 19.33 + 12.23; P ¼ 0.009; Figure 2B ). Assessing LVEF and SDF-1 expression as continuous variables, we observed a poor, but significant correlation between LVEF (%) and SDF-1 MFI (r ¼ 20.087, P ¼ 0.014). In a similar manner like in patients with ACS, platelet-bound SDF-1 is increased in patients with reduced LVEF independent of other factors including baseline medication and cardiovascular risk factors (data not shown). Furthermore, we assessed potential correlations among LVEF and initial or maximal myocardial necrosis markers (initial Tn: r ¼20.11, P ¼ 0.003; initial CK: r ¼20. 13 (LVEF ,55%; n ¼ 275) compared with patients with normal LVEF (.55%; n ¼ 291; P ¼ 0.007). In patients with SAP, plasma levels of SDF-1 did not show a significant difference between normal and reduced LV function (P ¼ 0.393). In patients with ACS, plasma levels of SDF-1 were significantly increased in patients with reduced LV function (n ¼ 137) when compared with patients with normal LV function (n ¼ 117; mean+SD: normal vs. reduced: 1940 + 390 pg/mL vs. 2122.4 + 512 pg/mL; P ¼ 0.004).
Platelet-bound stromal-cell-derived factor-1 and plasma levels of stromal-cell-derived factor-1
In a subgroup of 566 consecutive patients, we determined both platelet SDF-1 expression and plasma levels of SDF-1. We observed that platelet-bound SDF-1 poorly correlates with plasma SDF-1 (n ¼ 566, r ¼ 0.084, P ¼ 0.045; see Figure 3 ). In order to further investigate the association of platelet-bound SDF-1 with plasma SDF-1, we further analysed the correlation between these parameters. Checking interaction effects via a univariate ANOVA model showed no significant effect of either Platelet-bound stromal-cell-derived factor-1 correlates with platelet activation markers
It was previously reported that platelet-bound P-selectin, GPVI, and fibrinogen receptor GPIIb/IIIa are increased in patients with ACS. 28, 30 We found in this study that surface expression of SDF-1 on circulating platelets of patients with coronary artery disease correlated with the degree of P-selectin expression, thus systemic platelet activation (r ¼ 0.325, P , 0.001; Figure 4) , GPVI (r ¼ 0.277, P , 0.001; Figure 4 ), and PAC-1 (r ¼ 0.501, P , 0.001).
Platelet-bound stromal-cell-derived factor-1 correlates with the number of CD34 1 progenitor cells
As SDF-1 is a potent chemokine for CD34 þ progenitor cells, we asked whether there was a correlation between the expression of platelet SDF-1 and the number of circulating CD34 þ progenitor cells. In 144 consecutive patients with coronary artery disease, i.e. SAP (n ¼ 68) and ACS (n ¼ 76), we measured the number of CD34 þ progenitor cells using a standard protocol. 33 We found that increased progenitor cells circulate in the blood of patients with ACS in comparison to patients with SAP (absolute number of CD34 þ cells: ACS vs. SAP: mean+SD: 243.2 + 148 vs.
152.3 + 96.3, P ¼ 0.001; Figure 5 ). The number of CD34 þ progenitor cells in our population is increased in patients with ACS independent of cardiovascular risk factors, age, gender, and extension of coronary artery disease, documented as number of coronary arteries affected ( Table 3) . A not significant tendency (P ¼ 0.055) was observed for left ventricular function. On the other hand, intake of aspirin, but not other medication, seems to influence the number of CD34 þ cells in patients with ACS (P ¼ 0.017). Moreover, the number of CD34 þ progenitor cells correlated with the expression of platelet-bound SDF-1 (n ¼ 144, r ¼ 0.253, P ¼ 0.002; Figure 5C ), but not with the expression of P-selectin (r ¼ 0.086, P ¼ 0.304) or PAC-1 (r ¼ 2 0.70, P ¼ 0.448). Similar correlation was observed in a subpopulation of our study (n ¼ 56) between EPCs, defined as CD34 þ /CD133 þ cells, and plateletbound SDF-1 expression (r ¼ 0.352, P ¼ 0.008; Figure 5C ).
Discussion
The major findings of the present study are: (1) platelet-surface expression of SDF-1 is elevated in patients with ACS compared with patients with SAP; (2) it is increased in patients with reduced LV function compared with patients with normal LVEF; (3) it is slightly associated with plasma SDF-1 on admission day and correlates well with the degree of platelet activation; and (4) in a subgroup of patients, platelet-bound SDF-1 correlates with the number of circulating CD34 þ progenitor cells. CD34 þ cells have been described to be recruited to the ischaemic myocardium, differentiating into cardiac and vascular cells, and restoring cardiac function. 34 Recent studies have identified specific molecular signals, such as SDF-1/CXCR4, required for the interaction of bone-marrow-derived stem cells and damaged host tissues. SDF-1, the ligand for CXCR4, plays a crucial role in trafficking of CXCR4 þ bone-marrow-derived cells into peripheral blood
and their recruitment to damaged organs in vivo. SDF-1 secretion is increased during tissue damage such as myocardial infarction 34 and hind-limb ischaemia. 7, 20, 35 Local delivery of SDF-1 can enhance progenitor cell recruitment and neovascularization. 17 Combined delivery of SDF-1 and EPCs into sites of limb ischaemia promotes local EPC-mediated vasculogenesis. 17 SDF-1 has also been shown to promote bone marrow cell proliferation and angiogenesis. 17 Platelet-derived SDF-1 has been recently described to play a role in chemotaxis, adhesion, and differentiation of both murine and human progenitor cells mediating vascular regeneration in vivo. 14, 15, 24 Although SDF-1 effects have been relatively extensively studied in vitro and animal models, the role of SDF-1 in humans and especially in patients with myocardial ischaemia has been poorly described so far. The present study describes the expression of platelet-bound SDF-1 in circulating platelets in patients with ACS and/or reduced LV function, indicating that in cases where regeneration is needed platelet-bound SDF-1 is found to be increased. Endothelial progenitor cells are mobilized in response to vascular injury as a physiologic response. 36 Cardiovascular risk factors contribute to atherogenesis not only by inducing endothelial cell injury and dysfunction, but also by influencing the number and the function of EPCs, the cells responsible for vascular homeostasis and regeneration. 37 There are numerous physiological and pathological stimuli which influence the number of circulating EPCs such as regular physical activity, age, medications (statins, estrogens, PPAR-gamma agonists), as well as numerous inflammatory and haematopoietic cytokines including VEGF, SDF-1, granulocytecolony-stimulating factor, angiopoietin, and erythropoietin. 38 Endothelial injury in the absence of sufficient circulating progenitor cells affects the progression of cardiovascular disease in subjects with various cardiovascular risk factors. 37 Taking into consideration the known role of SDF-1 in mobilization and function of progenitor cells, the present study reports for the first time correlative findings between platelet-bound SDF-1 and number of progenitor cells in patients with coronary artery disease. On the other hand, ischaemia alone or any of its confounders could influence Platelet-bound SDF-1 in ACS the expression of platelet-bound SDF-1, the LV function, and the number of circulating EPCs in patients with ACS, and therefore further studies are needed to elucidate this pathophysiological mechanism. The present findings imply that increased surface expression of platelet-bound SDF-1 takes place in cases of acute or chronic tissue ischaemia, such as ACS or reduced systolic ventricular function, and in diseases or pathophysiological phenomena characterized by enhanced platelet activation such as stroke, sepsis, and inflammation. Therefore, in diseases where tissue regeneration is demanded, platelet-bound SDF-1 may be increased. In addition, platelet-surface-bound SDF-1 slightly correlates with plasma SDF-1 and with the number of circulating CD34 þ progenitor cells in patients with ACS, a phenomenon which could potentially and/or partially explain the reported mobilization of EPCs in those patients. Domiciliation of progenitor cells in peripheral tissue is a multistep cascade including the initial adhesion to activated endothelium or exposed matrix, transmigration through the endothelium, and invasion of the target tissue. 34 Platelets are the first circulating blood cells that adhere to vascular lesions and that accumulate in the microcirculation within ischaemic tissue. 31 Recently, we described that adherent platelets express substantial amounts of SDF-1, recruit EPCs in vitro and in vivo, and induce their subsequent differentiation towards an endothelial phenotype. 14,39 Moreover, we have observed that platelet-bound SDF-1 regulates recruitment of CD34 þ progenitor cells in vitro and in vivo, and differentiation of the latter into endothelial cells. 15 Therefore, although the exact clinical significance of platelet-bound SDF-1 in patients with ACS remains to be elucidated, it is tempting to speculate that plateletbound SDF-1 may play a role in vascular and myocardial remodelling or regeneration in patients with AMI. Understanding the role of platelets and platelet-derived SDF-1 in progenitor cell function and tissue regeneration may help to develop novel therapeutic strategies in treatment of patients with myocardial damage.
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